Recursion Pharmaceuticals, Inc. (BMV:RXRX)

Recursion Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-644.76	-463.66	-328.07	-239.48	-186.48
Depreciation & Amortization	83.7	36.49	24.4	11.76	8.41
Loss (Gain) From Sale of Assets	4.5	-	-	-	-
Asset Writedown & Restructuring Costs	28.04	0.11	1.19	2.81	-
Stock-Based Compensation	111.22	81.69	53.5	27.91	14.84
Other Operating Activities	31.8	32.96	5.45	8.56	4.92
Change in Accounts Receivable	32.94	-6.07	-7.76	-0	-5.38
Change in Accounts Payable	-2.62	6.44	-0.99	1.77	1.75
Change in Unearned Revenue	-36.77	-28.04	-41.08	110.32	-10
Change in Other Net Operating Assets	20.14	-19.08	5.56	-7.16	13.33
Operating Cash Flow	-371.81	-359.17	-287.78	-83.52	-158.61
Capital Expenditures	-6.47	-13.7	-11.96	-37.06	-39.8
Cash Acquisitions	-	277.1	1.84	-	-
Divestitures	-4.44	-	-	-	-
Sale (Purchase) of Intangibles	-2.16	-3.35	-0.6	-0.3	-
Investment in Securities	-3.81	-	0.48	230.61	-231.95
Investing Cash Flow	-16.87	260.06	-10.23	193.25	-271.74
Long-Term Debt Repaid	-8.43	-4.44	-0.77	-0.09	-12.8
Net Debt Issued (Repaid)	-8.43	-4.44	-0.77	-0.09	-12.8
Issuance of Common Stock	532.96	308.56	140.9	154.44	471.34
Other Financing Activities	-3	-	-	-	-
Financing Cash Flow	521.53	304.12	140.13	154.35	458.54
Foreign Exchange Rate Adjustments	18.04	-3.41	0.19	-0.31	-
Net Cash Flow	150.9	201.6	-157.69	263.76	28.18
Free Cash Flow	-378.28	-372.87	-299.74	-120.58	-198.41
Free Cash Flow Margin	-506.52%	-633.71%	-672.43%	-302.64%	-1949.42%
Free Cash Flow Per Share	-0.84	-1.36	-1.44	-0.69	-1.58
Cash Interest Paid	-	-	-	-	0.68
Levered Free Cash Flow	-208.52	-194.33	-187.37	-105.41	-121.93
Unlevered Free Cash Flow	-207.39	-193.35	-187.31	-105.37	-120.09
Change in Working Capital	13.69	-46.76	-44.26	104.92	-0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.